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Abstract
It has been emphasized that chronic generalized immune dysfunction is the leading event in the pathogenesis of HIV
infection, in which the contribution of dendritic cells (DCs) and regulatory T cells (Tregs) should not be underestimated. In
current study, we assessed the longitudinal changes of peripheral blood DC subsets and Tregs in chronically asymptomatic
treatment-naive HIV-1-infected patients during 60 weeks of antiretroviral therapy (ART), and compared with those in
healthy controls and long term non-progressors (LTNPs). Blood samples were collected at week 0, 4, 12, 24, 48 and 60 of
treatment to measure the counts of DC subsets and Tregs by flow cytometry and IFN-a plasma levels by ELISA. The counts
of myeloid dendritic cells (mDCs) increased during ART, reaching similar levels to healthy controls at week 60 post ART but
still lower than those of LTNPs. In HIV-1-infected patients, the mDCs counts were directly correlated with CD4 counts during
ART. Changes in mDCs at week 8 were positively correlated with the changes in CD4 counts at week 60 post ART. However,
the counts and function of plasmacytoid dendritic cells (pDCs) remained relatively stable during ART, and similar to those in
healthy controls and LTNPs. The percentage of Tregs increased before ART and normalized after ART. Importantly, we found
pDCs counts were associated with percentage of Tregs during ART, which may help in understanding of the role of these
cells in HIV infection.
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Introduction
HIV infection is characterized with an initial, occasionally
symptomatic acute phase followed by an asymptomatic period of
variable length culminating in clinically evident immunodeficiency
[1]. Recent findings have emphasized that chronic generalized
immune dysfunction is the leading event in the pathogenesis of
HIV infection, in which the contribution of dendritic cells (DCs)
and regulatory T cells (Tregs) should not be underestimated. DCs
are professional antigen-presenting cells required for generation of
adaptive immunity [2], and Tregs are essential for immune
nullipotency and immune suppression via cell-cell contacts or
cytokine secretion [3]. There are accumulating evidences that DCs
and Tregs may be valuable tools for modulating immunity in the
setting of chronic viral infections, and interactions between them
may play a crucial role in the balance of immunity and tolerance.
DCs are at the interface of innate and adaptive immunity,
which specialize in the initiation of adaptive immune responses to
invading pathogens such as HIV [4]. In human peripheral blood,
two main subsets have been identified according to their different
phenotypes and functions: myeloid and plasmacytoid DCs [5].
Myeloid DCs (mDCs) are more frequently found, which sense
both bacterial and viral pattern motifs through a broader range of
TLRs and secret high levels of IL-12 in response to activation [2].
Plasmacytoid DCs (pDCs), representing 0.2–0.8% of peripheral
blood mononuclear cells (PBMCs), selectively express Toll-like
receptor (TLR)-7 and TLR9, and are the most potent IFN-a-
producing cells in the body following viral stimulation [6]. The
role of DCs in HIV infection is still under debate because HIV has
evolved subtle strategies to hijack key cellular components in DCs,
leading to viral acquisition and dissemination while dampening or
delaying antiviral responses.
Tregs, representing approximately 5–10% of CD4+T cells in
the peripheral blood, profoundly inhibit T-cell activation, pro-
liferation and effector function, and play a role in the regulation of
chronic viral infections, including HIV. Several types of Tregs
have been characterized, most prominently natural and inducible
CD4+CD25+Tregs [7]. So far, Tregs are identified by expression
of a number of molecules, including the alpha chain of the IL-2
receptor (CD25), cytotoxic T-lymphocyte associated protein 4
(CTLA-4), glucocorticoid-induced tumor necrosis factor receptor
(GITR) and transcription factor forkhead box P3 (Foxp3) [7,8],
among which FoxP3 is proposed as an accurate marker for Tregs.
The role of Tregs in HIV infection is also paradoxical. On the one
hand, Tregs downregulate immune responses and limit the
magnitude of effector responses, resulting in failure to control
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immune activation, and thus protect from HIV progression [8].
Significant depletion and functional impairment of DCs have
been documented in HIV infection [9–12], but the mechanisms
underlying remain to be elucidated. Since the advent of highly
active antiretroviral therapy (HAART), HIV-infected patients
have experienced a significant delay in disease progression and
longer life expectancy. However, the impact of ART on DCs loss
or recovery in HIV infection is unclear, and few studies have
evaluated the longitudinal changes of peripheral blood DC subsets.
Several studies indicate that ART is not effective at increasing
blood mDCs [10,13,14], while others suggest that ART signifi-
cantly restores blood mDCs numbers [9,12,15]. As for the changes
of pDCs number and function after ART, there has been similar
controversy [9,10,12,14,15].
Nowadays, numerous studies have demonstrated the involve-
ment of Tregs in HIV infections, whereas, they can be good or evil
[8]. Results regarding the influence of ART on percentage and
counts of Tregs are not consistent among studies [16–21], and
longitudinal effects of ART on Tregs are rarely reported.
In this study, we described the longitudinal changes of
peripheral blood DC subsets and Tregs in a group of chronically
asymptomatic treatment-naive HIV-1-infected patients with initial
CD4 counts less than 350 cells/ul during 60 weeks of ART, and
compared with those in 15 HIV-uninfected healthy controls and
15 long term non-progressors (LTNPs).
Results
Viral loads and CD4+T cells counts before and after
initiation of ART
HIV-1 RNA viral loads (VLs) and CD4 counts were measured
in all 17 HIV-1-infected patients at week 0, 4, 8, 12, 24, 48 and 60
of ART (Table 1). VLs and CD4 counts were also measured in
LTNPs and CD4 counts in healthy controls for comparison. In
HIV-1-infected patients, VLs decreased significantly since initia-
tion of ART. Similarly, CD4 counts were markedly increased. In
healthy controls and LTNPs median CD4 counts (748 cells/ul and
693 cells/ul) were significantly higher than those in HIV-1-
infected patients at both week 0 (p,0.001) and week 60 (p,0.001).
Dynamics of DCs counts and IFN-a plasma levels during
ART
As shown in Fig. 1, we observed a significantly increase in
mDCs after ART, whereas no significant change in pDCs and
IFN-a plasma levels (Figure 1). The mDCs counts at w0 in HIV-1-
infected patients were significantly lower than those in healthy
controls (p,0.001) and LTNPs (p,0.001). However, the mDCs
counts at w60 increased to similar levels in healthy controls
(p=0.493) but still lower than those in LTNPs (p=0.014). The
counts of pDCs remained relatively stable during ART (6.09cells/
ul, 4.75cells/ul, 6.88cells/ul, 6.44cells/ul, 7.29cells/ul, 7.59cells/
ul and 8.07cells/ul at week 0, 4, 8, 12, 24, 48, 60 respectively, all
p.0.05 in comparison to w0) and were not distinguished from
those in HIV-1-uninfected controls (7.12cells/ul, both p.0.05 as
compared to w0 and w60) and the LTNPs (7.23cells/ul, both
p.0.05 as compared to w0 and w60). To interpret the function of
the blood pDCs, we also measured IFN-a plasma levels, and they
were not markedly affected by ART (data not shown).
Association of DCs counts with VLs and CD4 counts
In HIV-1-infected patients, no significant correlations were
observed between DC subsets counts and VLs (data not shown). In
contrast, a significant positively association were found between
mDCs counts and CD4 counts (r=0.40, p,0.001), as well as
pDCs counts and CD4 counts (r=0.319, p=0.001) (Figure 2 A–
B). Changes in mDCs at week 8 were negatively correlated with
the changes in viral loads at week 60 (r=20.551, p=0.022) and
positively correlated with the changes in CD4 counts at week 60
post ART (r=0.566, p=0.018) (Figure 2 C–D). However, there
were no similar correlations of pDCs with VLs and CD4 counts
(data not shown).
Dynamics of the percentage and counts of Tregs during
ART
As shown in figure 3, the percentage was significantly reduced
during ART, from 6.45% at w0 to 4.24% at w60 (6.45%, 6.26%,
5.51%, 5.04%, 4.97%, 4.95% and 4.24% at week 0, 4, 8, 12, 24,
48 and 60 respectively), and the corresponding p-values are 0.627,
0.102, 0.016, 0.048, 0.047, 0.001, compared to w0. In addition,
the percentage of Tregs at w0 in HIV-1-infected patients was
significantly higher than that in healthy controls (4.16%, p=0.013)
and LTNPs (2.88%, p=0.001). After 60 weeks of ART, the Tregs
percentage in HIV-1-infected patients was equal to that in the
healthy controls (p=0.862), but still lower than that in LTNPs
(p=0.021). Unexpectedly, the Tregs percentage in LTNPs is lower
than the healthy controls (p=0.002). And the Tregs counts in
HIV-1-infected patients were not significantly changed during
ART, ranging from 13.8 cells/ul to 17.4 cells/ul (13.8 cells/ul,
16.9 cells/ul, 15.9 cells/ul, 14.2 cells/ul, 17.4cells/ul and 15.3
cells/ul at week 0, 4, 8, 12, 24, 48 and 60 respectively; all p.0.05,
compared to w0).
Association between DCs counts and Tregs counts
Interestingly, pDCs counts were positively associated with Tregs
percentage (r=0.343, p,0.001), but there were no correlations
between mDCs counts and Tregs percentage (r=0.181, p=0.055)
(Figure 4).
Discussion
In the present study, we followed the counts of peripheral blood
DC subsets, Tregs and IFN-a plasma levels in chronic HIV-1-
infected patients over 60 weeks of ART,and compared with those
in healthy controls and LTNPs. All chronic patients were given
AZT+3TC+NVP or D4T+3TC+NVP, showing excellent adher-
ence during treatment. As a result, a great curative effect of ART
was achieved, with the viral loads falling below the limit of
detection within 24 weeks, as well as CD4 counts increasing by
approximately 150 cells/ul after 60 weeks of ART in all chronic
HIV-1-infected patients.
We find that the impacts of ART on the counts and function of
blood DC subsets in the HIV-1-infected patients are significantly
different. The results indicated that mDCs counts in HIV-1-
infected patients before ART were significantly lower than healthy
controls, which were consistent with previous reports [9–13].
However, the mechanisms used by HIV to affect DCs are not fully
understood. It could be due to HIV induced or HIV-related cell
death. Blood mDCs counts began to increase early at 8 weeks post
ART, reaching to the level of the healthy controls after 60 weeks.
Our results confirm findings by other reports [11,22]. In contrast,
LTNPs had relatively normal levels of blood DCs [13]. After 60
weeks of ART, the mDCs counts in the chronic HIV-1-infected
patients still lower than those in LTNPs, suggesting that mDCs
may protect HIV-infected patients from progress to AIDS. The
mechanisms that account for the increase in circulating mDCs
after ART are likely due to the redistribution of mDCs from
lymphoid tissue to blood. In addition, it is also possible that the
Impact of ART on DC Subsets and Tregs
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Age VL(copies/ml) CD4+T cell counts(cells/ul)
NO. (years) ART w0 w4 w12 w24 w60 Sex Tr w0 w4 w8 w12 w24 w48 w60
1 42 AZT+3TC+NVP 6158 41 44 ,40 ,40 M Ho 25 117 190 187 174 190 265
2 29 D4T+3TC+NVP 24185 533 62 118 44 M Ho 244 210 187 231 330 308 257
3 32 D4T+3TC+NVP 5089 352 ,40 73 ,40 F ND 248 302 417 385 394 412 532
4 31 D4T+3TC+NVP 68639 43701 ND 133 ,40 M Ho 196 416 294 302 322 407 380
5 33 AZT+3TC+NVP 48808 1490 341 ,40 ,40 M Ho 159 204 251 233 205 418 290
6 41 D4T+3TC+NVP 397739 1034 735 59 47 M Ho 341 400 320 228 334 524 535
7 37 D4T+3TC+NVP 1837 257 ,40 ,40 ,40 M Ho 249 205 306 336 354 384 368
8 36 D4T+3TC+NVP 8016 113 ,40 ,40 ,40 M Ho 227 366 366 344 411 271 363
9 30 D4T+3TC+NVP 20206 130 ,40 ,40 45 M Ho 116 232 234 136 250 355 371
10 27 D4T+3TC+NVP 41811 836 179 ,40 ,40 M Ho 267 319 416 473 373 378 490
11 28 AZT+3TC+NVP 10416 288 46 71 ,40 M Ho 237 228 260 331 208 350 425
12 38 D4T+3TC+NVP 1528 3503 1435 ND ,40 F He 215 216 235 201 251 247 234
13 29 D4T+3TC+NVP 67897 1126 134 ,40 ,40 M Ho 190 224 333 270 350 390 341
14 28 D4T+3TC+NVP 46227 295 ,40 ,40 ,40 M Ho 322 308 280 302 290 414 303
15 26 D4T+3TC+NVP 20977 578 104 45 ,40 M Ho 66 169 160 193 258 186 170
16 42 D4T+3TC+NVP 58578 1655 150 266 ,40 M Ho 124 203 230 285 269 288 310
17 30 D4T+3TC+NVP 46746 130 140 ,40 ,4 0 M H o 3 4 2 92 84 11 0 0 1 9 2 1 6 7
Median 31 24185 533
** 83
** ,40
** ,40
** 215 224
** 260
** 270
** 290
** 355
** 341
**
ART, antiretroviral therapy; AZT, zidovudine; 3TC, lamivudine; NVP, nevirapine; d4T, stavudine; F, female; M,male; ND, not determined; Tr: transmission route; Ho:
homosexual; He: heterosexual;
**p,0.01, compared to week 0.
doi:10.1371/journal.pone.0037966.t001
Figure 1. Longitudinal changes in DC subsets and IFN-a plasma levels during ART (weeks). (A–C) Longitudinal changes in counts of
mDCs, pDCs and IFN-a plasma levels in HIV-1-infected patients during ART. (D–F) Comparisons of mDCs, pDCs and IFN-a plasma levels among HIV-1-
infected patients at week 0, week 60, healthy controls and LTNPs. **p,0.01, *p,0.05.
doi:10.1371/journal.pone.0037966.g001
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replication, by way of either expansion of existing mDCs or thymic
generation [23]. This conclusion is also supported by the findings
that ART reduced activation of mDCs and expression of
CCR7and caspase-3, and transiently restored mDCs counts in
monkeys with progressive infection [9,24,25]. What’ more, it is
reported that the mDCs precursors increased above normal levels
during chronic infection, particularly in LTNPs [13]. Conversely,
Schmidt et al. [26] reported that no significant differences were
observed in changes of absolute mDCs counts after 12-month
ART.
In contrast to mDCs, our results showed that pDCs counts in
HIV-1-infected patients did not decline before ART compared to
those in healthy controls nor increased during ART. Even though
there were no differences in pDCs counts between HIV-1-infected
patients and healthy controls and LTNPs, in a more recent report,
Geng et al. [27] showed that there were significantly lower pDCs
counts in rapid progressors compared with typical progressors and
healthy controls, suggesting that factors affecting pDCs counts
were not just HIV. However, others described a reduction of
pDCs counts in HIV-infected patients, and an impaired restora-
tion of pDCs counts after ART [11,22].
Reasons that account for the conflicting results of DCs counts
may be as follows [10,14,22,28]. (1) There was a great diversity
among the study subjects. For example, some patients had high
VLs and low CD4 counts before ART, while others were
complicated with opportunistic infections or at different stages of
disease progression. (2) Different DCs markers were used in
different studies, such as HLA-DR+CD11c+Lin2 [11,15],
CD4+CD11c+Lin2 [26,29], BDCA1+BDCA22 [22] for mDCs,
and CD123
highHLA-DR+Lin2 [11,15], CD4+CD11c2Lin2
[26,29], BDCA12BDCA2+ [22] for pDCs. (3) There might be
remarkable individual differences across studies, such as ethnics
and treatment sensitivity. (4) The time to initiate ART, existence of
HIV resistant strains, drug toxicity, and poor patient adherence to
medication may affect DCs counts during ART. In addition, as
relatively rare cells in peripheral blood, DCs also have higher
variability. Thus DCs quantification requires the acquisition of
large numbers of events and a rare event analysis. Many studies
have indicated that DCs counts are of potential interest in clinical
immunology, thus, standardization between the different labora-
tories involved is urgently needed.
IFN-a in vivo is mainly produced by pDCs, following
interactions with HIV-infected cells or TLR ligands originated
from gut microbial translocation [30]. Our observations showed
that there was no decrease in IFN-a plasma levels in HIV-1-
infected patients before ART or a change of IFN-a levels during
ART, which was similar to the changes of pDCs counts and
consistent with data reported by others [10,29]. Nevertheless,
there are also studies demonstrating that IFN-a production by
virus stimulated PBMCs are reduced in HIV-infected patients
[11,15].The reason for discrepancy between them remains
undetermined.
To understand whether the increase of mDCs is linked to
plasma viral loads and CD4 counts during ART, we investigated
the correlations among them. Our results showed that the chronic
HIV-1-infected patients indeed had significantly positive correla-
tion between mDCs counts and CD4 counts during ART. CD4
counts are usually considered as an indicator of preserved function
of the immune system. The increase of mDCs counts after ART
related to CD4 counts may also suggest the restoration of immune
responses. It is notable that changes in mDCs at week 8 were
negatively correlated with the changes in viral loads and positively
correlated with the changes in CD4 counts at week 60 post ART,
Figure 2. The association of DC subsets with viral loads and CD4+Tcells. (A–B) Correlation between DC subsets counts and plasma viral
loads, CD4+Tcells counts during ART. (C–D) Correlation between change in counts of DC subsets at week 8 and the change in plasma viral loads,
CD4+Tcells counts at week 60 post ART.
doi:10.1371/journal.pone.0037966.g002
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for predicting the immune reconstitution and mDCs.
As just discussed for DCs, the impact of ART on the percentage
and counts of Tregs in HIV-infected patients are also full of
contradictions. We show that compared to the healthy controls,
Tregs percentage in HIV-1-infected patients was significantly
increased before ART, and decreased to normal levels after 60
weeks of ART. Additionally, LTNPs have the lowest frequency.
These results are bolstered by recent studies showing that there
was a significant higher percentage in patients with lower CD4
counts and ART reduced Tregs frequencies [17,19,31]. It is
reported that Tregs are inversely correlated with activation of T
cells [20,32,33], and elite controllers have lower Tregs frequencies
compared to chronic HIV-infected patients, including patients on
ART [33]. In this context, it is suggested that low Tregs may play
a positive role in the HIV infection as they can maintain strong
antiviral immune responses at the cost of hyperactivation.
Mechanisms underlying loss of Tregs frequency during ART are
not well understood, but could include Tregs redistribution and
reduced thymic/virus-induced proliferation, or lower non-Treg
Figure 3. Longitudinal changes in the percentage and counts of Tregs during ART (weeks). (A–B) Longitudinal changes in the percentage
and counts of Tregs in HIV-1-infected patients during ART. (C–D) Comparisons of the percentage and counts of Tregs among HIV-1-infected patients
at week 0, week 60, healthy controls and LTNPs. **p,0.01, *p,0.05.
doi:10.1371/journal.pone.0037966.g003
Figure 4. The association of DC subsets with Tregs percentage. (A) Correlation between mDCs counts and Tregs percentage during ART. (B)
Correlation between pDCs counts and Tregs percentage during ART.
doi:10.1371/journal.pone.0037966.g004
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after ART [17,33–35]. Nevertheless, some authors observed that
there was an increase or no change in Tregs percentage during
ART [18,21]. Additionally, Jiao et al. [20] demonstrated that
efficient ART resulted in Treg frequency normalizing in complete
responders to the treatment but not in non-responders. In contrast,
Tregs counts in HIV-1-infected patients before ART were not
different from healthy controls [16], and were not changed during
ART. Interestingly, other studies suggested that there was an
increase or a decrease in Tregs counts after ART [17,18,21].
Numerous factors such as the timing and intensity of ART and
methodological discrepancies of the Tregs detection have con-
siderable impacts on the changes of Tregs during ART. The
findings in this context are very preliminary and much more
detailed investigations need to be carried out.
There is accumulating evidence that DCs and Tregs are
interacting with each other by cell-cell contacts and soluble factors
[36,37]. For example, it is suggested that interactions between
HIV and DCs lead to the development of semimature DCs which
induce Tregs production, while these semimature DCs disap-
pearance correlates with the initiation of ART [35]. Another study
reported that HIV-stimulated pDCs could induce Tregs produc-
tion by expression of indoleamine 2, 3-dioxygenase, and the Tregs
induced by pDCs were shown to inhibit the maturation of
bystander conventional DCs [38]. However, the role of the
interplay between DCs and Tregs in HIV infection still needs to be
clarified. Interestingly, we showed that pDCs counts were
positively associated with Tregs percentage during ART.
The present study examined the longitudinal changes of
peripheral blood DC subsets and Tregs in a group of chronically
asymptomatic treatment-naive HIV-1-infected patients over 60
weeks of ART, and compared with those in healthy controls and
LTNPs. Although the mechanisms responsible for the observed
impact of ART on them remain undefined, our data indicate that
mDCs counts reduced in chronic HIV-1-infected patients and
normalize after 60 weeks of ART but still lower than those in
LTNPs, together with fully suppressed VLs and increased CD4
counts. However, the counts and function of pDCs were relatively
stable during ART. Our longitudinal data from ART-treated
subjects suggest that the mDCs defects may be reversible and
mDCs (not pDCs) are likely important APCs that bridge the gap
between innate and adaptive immunity in HIV infection. What’s
more, Tregs percentage increased before ART and normalized
after ART, suggesting that low Tregs percentage may benefit
antiviral immune responses in HIV infection. Information
regarding the dynamics of DC subsets and Tregs during ART
may improve our understanding of the role of these cells in HIV
infection.
Materials and Methods
Subjects
There were 17 chronically asymptomatic treatment-naive HIV-
1-infected patients enrolled in our study. Inclusion criteria for the
HIV-1+group included CD4 counts less than 350cells/ul and no-
opportunistic infection within the previous three months. Patients
with pregnancy, active tuberculosis, acute infectious diseases or
serious liver/renal dysfunction were excluded from the study. All
individuals received ART, which included two nucleoside reverse-
transcriptase inhibitors (NRTIs) plus one non-nucleoside reverse
transcriptase inhibitor (NNRTI) (Table 1). After 24 weeks of ART,
VLs in almost all patients were below the lower detection limit.
Additional 15 HIV-uninfected age-matched healthy adults and 15
long term non-progressors (LTNPs) were recruited as controls.
The definition of LTNPs was HIV-infected for greater than 10
years with lower detectable viremia and high CD4 counts without
ART. Blood was collected at week 0, 4, 12, 24, 48 and 60 of
treatment. All subjects were from Beijing You’an Hospital, Capital
Medical University. The study was approved by the Beijing
You’an Hospital Research Ethics Committee, and written
informed consent was obtained from each subject.
Enumeration of DC Subsets and Tregs in PBMCs
PBMCs were isolated by density gradient centrifugation using
Ficoll-Hypaque (Amersham Pharmacia Biotech, Piscataway, NJ)
from whole blood. Four-color flow cytometric analysis was
performed using FACS Calibur (BD Biosciences, San Diego,
USA) and data of DCs and Tregs were collected using identical
instrument settings. All data obtained was analyzed using FlowJo
(Treestar, Ashland, OR). The counts of blood DCs and Tregs
were calculated using the dual platform TruCOUNT assay (see
below).
To identify DCs, the following antibodies from BD Pharmingen
(San Diego, USA) were used: CD4-PerCP, Lin-FITC, HLA-Dr-
PE and CD11c-APC. At least 200,000 events were acquired for
each sample. mDCs were identified as Lin2HLA-DR+CD11c+,
while pDCs were Lin-HLA2DR+CD11c2 [26,39,40]. DCs
counts were calculated as follows, utilizing hemocytometer data
for lymphocytes and monocytes and flow cytometry data for
windows [10]: mDCs/pDCs per ul of blood=counts of (mono-
cytes+lymphocytes)/ul6(number of events in the population [ie,
in R3 or R4, Figure 5]/number of PBMCs).
For staining of Tregs, the cells were first stained with CD3-
PerCP, CD4-FITC and CD25-PE (BD Pharmingen, San Diego,
USA), then permeabilized and fixed using eBioscience fix/perm
(eBioscience, San Diego, USA) according to the manufacturer’s
instructions. After 30-minute permeabilization, FoxP3-FITC
(eBioscience, San Diego, USA) was added for another 30 minutes.
Tregs were identified as CD3+CD4+CD25+Foxp3+. The counts
of Tregs were deduced from the CD4+T cells counts multiplied by
the proportion of Tregs in CD4+T cells (Figure 6).
Figure 5. Rare event analysis of DC subsets by flow cytometry:
mDCs (R3) and pDCs (R4).
doi:10.1371/journal.pone.0037966.g005
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The IFN-a plasma levels were detected using a human IFN-a
ELISA kit and performed according to the manufacture’s
instruction (Mabtech, USA). Sensitivity of the assay was 10-
3160 pg/ml. The limit of detection of this assay is 3 pg/ml.
Viral Load
Plasma HIV-1 RNA was quantified by real time-PCR (Roche,
Germany) and the sensitivity of detection of this super sensitive
assay was 40 copies/ml. Values below the limits of detection were
treated as 20 copies/ml.
Statistical analysis
Data analysis was performed with SPSS 16 software (SPSS Inc,
Chicago, IL). The Mann-Whitney test was utilized for compar-
isons between two independent groups. The Wilcoxon signed rank
test was used for comparisons within subjects. The correlations
between variables were calculated using the Spearman’s rank
correlation test and linear regression analysis were plotted using
the Graph Pad Prism software (v 5.0). All statistical analyses
assumed a two-sided significance at p values,0.05.
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